Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALML3 | P27482 | 6/20 | 0.55 |
| ▸ | MAOA | P21397 | 10/20 | 0.47 |
| ▸ | MAOB | P27338 | 3/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3750484 | 0.88 | CALML3 (0.41) | CALML3MAOAMAOBCYP3A4CYP2D6 | |
| SCHEMBL13054837 | 0.88 | CALML3 (0.41) | CALML3MAOAMAOBCYP3A4CYP2D6 | |
| SCHEMBL14025125 | 0.87 | CALML3 (0.41) | CALML3MAOAMAOBCYP2C19CYP3A4 | |
| SCHEMBL13081231 | 0.86 | CALML3 (0.64) | CALML3MAOAMAOBCYP2C19CYP3A4 | |
| SCHEMBL7003065 | 0.84 | CALML3 (0.55) | CALML3MAOAMAOBCYP2C19CYP3A4 | |
| SCHEMBL7837659 | 0.84 | CALML3 (0.55) | CALML3MAOAMAOBCYP2C19CYP3A4 | |
| SCHEMBL3758264 | 0.80 | CALML3 (0.54) | CALML3MAOAMAOBCYP2C19CYP3A4 | |
| SCHEMBL3758259 | 0.79 | CALML3 (0.53) | CALML3MAOAMAOBCYP2C19CYP3A4 | |
| SCHEMBL3757473 | 0.78 | CALML3 (0.48) | CALML3MAOAMAOBCYP2C19CYP3A4 | |
| SCHEMBL5833572 | 0.78 | CALML3 (0.48) | CALML3MAOAMAOBCYP2C19CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100298384-A1 | NOVEL OXAZOLIDINONE COMPOUNDS AS ANTIINFECTIVE AGENTS | DR. REDDY'S LABORATORIES LTD. (IN) | 2010-11-25 | — | — | US | disclosed |
| US-20100298384-A1 | NOVEL OXAZOLIDINONE COMPOUNDS AS ANTIINFECTIVE AGENTS | DR. REDDY'S LABORATORIES LTD. (IN) | 2010-11-25 | — | — | US | disclosed |
| WO-2008143649-A2 | NOVEL OXAZOLIDINONE COMPOUNDS AS ANTIINFECTIVE AGENTS | DR. REDDY'S LABORATORIES LIMITED (IN) | 2008-11-27 | — | — | WO | disclosed |
| WO-2008143649-A2 | NOVEL OXAZOLIDINONE COMPOUNDS AS ANTIINFECTIVE AGENTS | DR. REDDY'S LABORATORIES LIMITED (IN) | 2008-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298384-A1 | NOVEL OXAZOLIDINONE COMPOUNDS AS ANTIINFECTIVE AGENTS | OXA1L, MIF, VIP | CALML3 4408/4885MAOA 3034/4885MAOB 2709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.